Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.

The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing disease prevalence, advancements in diagnostic techniques, and the introduction ...

Investigators assessed silmitasertib monotherapy in patients who had failed first-line hedgehog pathway inhibitors, with 27.3% also failing second-line PD-1 inhibitors such as cemiplimab (Libtayo) or ...

The vast majority of Medicare's top-selling brand-name oncology drugs in 2022 provided high added therapeutic benefit. Ten drugs were classified as low or no added therapeutic benefit compared ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...